Who Paid My Doc
Daniel Erdman
Obesity Medicine Saratoga, CA Medical Doctor
NPI 1730152208 CMS profile 982253
14375 Saratoga Ave Ste 101, Saratoga, CA 95070
General payments
$144
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Erdman of Saratoga, CA is reported in the CMS Open Payments database as having received $144 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $144 | 2 |
Beside peers
- Daniel Erdman
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Daniel Erdman were reported at $144. Among 30 Obesity Medicine profiles paid that year, the median was $190 and the middle half received between $125 and $2,258.
Show as a table
| Year | Daniel Erdman | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $128 | $31–$684 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $140 | $105–$307 | $132 |
| 2022 | $0 | $94 | $36–$376 | $149 |
| 2023 | $0 | $118 | $44–$1,006 | $160 |
| 2024 | $0 | $122 | $75–$730 | $164 |
| 2025 | $144 | $190 | $125–$2,258 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$18,356
Medicare patients
99
Services billed
4,209
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Arthritis | 53% | |
| Cancer | 28% | |
| Chronic kidney disease | 19% | |
| Diabetes | 18% | |
| COPD | 18% | |
| Ischemic heart disease | 17% | |
| Osteoporosis | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadobutrol, 0.1 ml A9585 | Office | 16 | 1,400 | $378 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 26 | 2,700 | $241 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obesity Medicine in California
Related records
Obesity Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.